Home » Topics » BioWorld Science

BioWorld Science
RSS

Squalamine enters phase I for the treatment of cancer

Dec. 22, 1997

FDA Advisory Committee does not recommend approval for DepoCyt

Dec. 19, 1997

Hemolink enters phase II trials for second indication

Dec. 19, 1997

VIMRx and Baxter form new company focused on cell therapy

Dec. 19, 1997

Nutropin AQ also wins FDA approval

Dec. 19, 1997

Mechanism of exocrine pancreas secretion assessed for herbal medicine

Dec. 19, 1997

S-5920 effective in rat model of acute pancreatitis

Dec. 19, 1997

Positive phase IIa results reported for Cortecs' oral insulin

Dec. 19, 1997

Oral neuraminidase inhibitor advances to phase II/III

Dec. 19, 1997

CholestaGel enters phase III testing

Dec. 19, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...